Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Segment Profit Share & Royalty Expense in Cost of Sales by Year
Segment Profit Share & Royalty Expense in Cost of Sales ($M) ($M)
Amgen Segment Profit Share & Royalty Expense in Cost of Sales: $2,192M in FY2025, up 26.0% from a year earlier.
Latest, FY2025
2,192
Period ended Dec 31, 2025
Change on a year earlier
+26.0%
1,740 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note 2 Segment Expense Disaggregation (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Segment Profit Share & Royalty Expense in Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,192 | +26.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,740 | +57.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,104 | +75.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 630 | – | Form 10-K (filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Segment Profit Share & Royalty Expense in Cost of Sales ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/seg-royalty-cogs
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.